Allergan Aesthetics Gains CHMP Positive Opinion for Boey TrenibotulinumtoxinE Across 30 EEA Markets

A new botulinum toxin serotype is moving toward EU commercialization: Allergan Aesthetics, an AbbVie company, has received a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) recommending approval of Boey® (trenibotulinumtoxinE) for the temporary improvement of moderate to severe glabellar lines in adults where the condition carries an important psychological impact. The European Commission decision, expected within months, would extend marketing authorization across all 30 European Economic Area countries via the centralized procedure.

For manufacturing and QA leads, the regulatory milestone triggers immediate preparation requirements. Allergan Aesthetics has confirmed it is preparing for commercial launch and will begin healthcare professional training programs ahead of authorization. Separately, marketing authorization submissions for trenibotulinumtoxinE remain under review in multiple non-EU jurisdictions, broadening the supply network planning horizon.

The CHMP opinion is underpinned by data from two pivotal Phase 3 trials (M21-500 and M21-508), both of which met all primary and secondary endpoints. Onset of action was observed as early as eight hours post-administration, the earliest assessment timepoint, with efficacy duration of two to three weeks. Treatment-emergent adverse events were comparable to placebo across single and up to three consecutive treatment cycles, a safety profile that will inform labeling and pharmacovigilance obligations under the eventual marketing authorization.

If approved, Boey® would represent the first and only botulinum neurotoxin serotype E available to adult patients in the EU aesthetics market, a distinction that carries distinct cold-chain, fill-finish, and batch release considerations relative to the established serotype A products currently dominating the category. Regulatory affairs teams at competing manufacturers and contract organizations should note the precedent this sets for serotype E dossier construction under EMA centralized procedure requirements.

The European Commission's formal decision will determine the precise label, post-authorization commitments, and any risk management plan obligations that will govern Boey®'s entry into the 30 EEA markets.

Source: AbbVie News Center via PRNewswire, 21 May 2026.